Loading...
In recent years, clinicians have sought a potent antiretroviral combination that can be administered once daily; the hope being that once-daily dosing would improve quality of life and adherence, thus increasing the likelihood of treatment success. Emtricitabine (FTC) is a very potent cytidine nucleoside analogue with a long plasma half-life. Based on the results of a small study, which showed that the combination of ddI + efavirenz + emtricitabine given once daily suppressed viral loads to <50 copies/mL in 93% of patients at 24 weeks, a larger international phase III trial (the FTC-301A Study) was designed. This manufacturer-sponsored trial used the same drug combination and compared it in a randomized, double-blind, double-dummy design wi…